Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 3122-3125

  Spellberg, Brad ^a,b,i   Andes, David ^c   Perez, Mario ^d   Anglim, Anne ^e   Bonilla, Hector ^f   Mathisen, Glenn E ^g   Walsh, Thomas J ^h   Ibrahim, Ashraf S ^a,b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e Long Beach Department of Health and Human Services   (United States)

^f SUMMA HEALTH SYSTEM   (United States)

^g OLIVE VIEW UCLA MEDICAL CENTER   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ RB2 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; DEFERASIROX; MICAFUNGIN; POSACONAZOLE;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CLINICAL ARTICLE; DRUG SAFETY; FEMALE; HUMAN; IRON CHELATION; KIDNEY FUNCTION; LIVER FUNCTION; MALE; MUCORMYCOSIS; OPEN STUDY; PRIORITY JOURNAL; RASH; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; BENZOIC ACIDS; CHELATION THERAPY; EXANTHEMA; FEMALE; HUMANS; IRON CHELATING AGENTS; MALE; MIDDLE AGED; MUCORMYCOSIS; TREATMENT OUTCOME; TRIAZOLES;

EID: 67649935369     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00361-09     Document Type: Article

References (13)

1. Boelaert, J. R., M. de Locht, and Y. J. Schneider. 1994. The effect of deferoxamine on different zygomycetes. J. Infect. Dis. 169:231-232.
2. Boelaert, J. R., M. de Locht, J. Van Cutsem, V. Kerrels, B. Cantinieaux, A. Verdonck, H. W. Van Landuyt, and Y. J. Schneider. 1993. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J. Clin. Investig. 91:1979-1986.
3. Cappellini, M. D. 2005. Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Pract. Res. Clin. Haematol. 18:289-298.
4. De Pauw, B., T. J. Walsh, J. P. Donnelly, D. A. Stevens, J. E. Edwards, T. Calandra, P. G. Pappas, J. Maertens, O. Lortholary, C. A. Kauffman, D. W. Denning, T. F. Patterson, G. Maschmeyer, J. Bille, W. E. Dismukes, R. Herbrecht, W. W. Hope, C. C. Kibbler, B. J. Kullberg, K. A. Marr, P. Munoz, F. C. Odds, J. R. Perfect, A. Restrepo, M. Ruhnke, B. H. Segal, J. D. Sobel, T. C. Sorrell, C. Viscoli, J. R. Wingard, T. Zaoutis, and J. E. Bennett. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46:1813-1821.
5. Hibbett, D. S., M. Binder, J. F. Bischoff, M. Blackwell, P. F. Cannon, O. E. Eriksson, S. Huhndorf, T. James, P. M. Kirk, R. Lucking, H. Thorsten Lumbsch, F. Lutzoni, P. B. Matheny, D. J. McLaughlin, M. J. Powell, S. Redhead, C. L. Schoch, J. W. Spatafora, J. A. Stalpers, R. Vilgalys, M. C. Aime, A. Aptroot, R. Bauer, D. Begerow, G. L. Benny, L. A. Castlebury, P. W. Crous, Y. C. Dai, W. Gams, D. M. Geiser, G. W. Griffith, C. Gueidan, D. L. Hawksworth, G. Hestmark, K. Hosaka, R. A. Humber, K. D. Hyde, J. E. Ironside, U. Koljalg, C. P. Kurtzman, K. H. Larsson, R. Lichtwardt, J. Longcore, J. Miadlikowska, A. Miller, J. M. Moncalvo, S. Mozley-Standridge, F. Oberwinkler, E. Parmasto, V. Reeb, J. D. Rogers, C. Roux, L. Ryvarden, J. P. Sampaio, A. Schussler, J. Sugiyama, R. G. Thorn, L. Tibell, W. A. Untereiner, C. Walker, Z. Wang, A. Weir, M. Weiss, M. M. White, K. Winka, Y. J. Yao, and N. Zhang. 2007. A higher-level phylogenetic classification of the Fungi. Mycol. Res. 111:509-547.
6. Hohneker, J. A. December 2007, posting date. Important information about Exjade (deferasirox) tablets for oral suspension. Novartis, East Hanover, NJ. http://www.fda.gov/medwatch/SAFETY/2007/Exjade-DHCPL-Dec2007.pdf.
7. Ibrahim, A. S., J. E. Edwards, Jr., Y. Fu, and B. Spellberg. 2006. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J. Antimicrob. Chemother. 58:1070-1073.
8. Ibrahim, A. S., T. Gebermariam, Y. Fu, L. Lin, M. I. Husseiny, S. W. French, J. Schwartz, C. D. Skory, J. E. Edwards, Jr., and B. J. Spellberg. 2007. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J. Clin. Investig. 117:2649-2657.
9. Reed, C., A. Ibrahim, J. E. Edwards, Jr., I. Walot, and B. Spellberg. 2006. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob. Agents Chemother. 50:3968-3969.
10. Roden, M. M., T. E. Zaoutis, W. L. Buchanan, T. A. Knudsen, T. A. Sarkisova, R. L. Schaufele, M. Sein, T. Sein, C. C. Chiou, J. H. Chu, D. P. Kontoyiannis, and T. J. Walsh. 2005. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 41:634-653.
11. Soummer, A., A. Mathonnet, O. Scatton, P. P. Massault, A. Paugam, V. Lemiale, J. P. Mira, E. Dannaoui, A. Cariou, and O. Lortholary. 2008. Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis. Antimicrob. Agents Chemother. 52:1585-1586.
12. Spellberg, B., J. Edwards, Jr., and A. Ibrahim. 2005. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin. Microbiol. Rev. 18:556-569.
13. Vichinsky, E. 2008. Clinical application of deferasirox: practical patient management. Am. J. Hematol. 83:398-402.